Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
The company impresses investors, but money’s running short.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
